Abstract: Asthma is a chronic inflammatory airway disease that affects millions of people worldwide. Horses develop asthma spontaneously and serve as a relevant model for multiple phenotypes and endotypes of human asthma. In horses with equine asthma (EA), environmental organic dust triggers increased inflammatory cytokines, excess airway mucus, reversible bronchoconstriction, and airway inflammation. In horses with severe EA (sEA), lower airway inflammation is invariably neutrophilic, making sEA a potential model for severe neutrophilic asthma in humans. Alveolar macrophages (AM) and airway neutrophils contribute to lower airway inflammation and tissue damage through the release of cytokines and toxic mediators including reactive oxygen species. Previous work shows that the Myristoylated Alanine Rich C Kinase Substrate (MARCKS) protein is increased in activated macrophages and neutrophils and is an essential regulator of inflammatory functions in these cell types. We hypothesized that MARCKS protein would be increased in bronchoalveolar lavage (BAL) cells from horses with EA, and that in vitro inhibition of MARCKS with a specific inhibitor peptide known as MyristoylAted N-terminal Sequence (MANS), would diminish cytokine production and respiratory burst. Methods: BAL cells from two populations of healthy and asthmatic horses were evaluated for cytology and MARCKS protein analysis. Isolated alveolar macrophages and peripheral blood neutrophils were stimulated with zymosan to evaluate MARCKS inhibition in cytokine secretion and respiratory burst. Results: We found increased levels of normalized MARCKS protein in total BAL cells from horses with asthma compared to normal horses. MARCKS inhibition with the MANS peptide had no effect on zymosan-stimulated release of tumor necrosis factor alpha (TNFα) or interleukin-8 (IL-8) from alveolar macrophages but did attenuate zymosan-stimulated respiratory burst in both alveolar macrophages and peripheral blood neutrophils. Conclusions: These findings point to a possible role for MARCKS in the pathophysiology of neutrophilic equine asthma and support further investigation of MARCKS as a novel anti-inflammatory target for severe neutrophilic asthma.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article investigates the role of a protein called MARCKS in equine asthma (EA), a form of asthma in horses, which might also shed light on human asthma. It was found that the MARCKS protein was higher in horses with EA and it could be a potential target for therapeutic treatment.
Background
Equine asthma (EA) is a disease in horses, which parallels multiple phenotypes of human asthma.
The study is rooted in the hypothesis that Myristoylated Alanine Rich C Kinase Substrate (MARKS) protein, which is critical in regulating inflammation in alveolar macrophages and neutrophils (two types of defense cells in mammals), might be playing an essential role in EA.
Environmental organic dust is reported to intensify the symptoms in horses with severe EA (sEA) like excess mucus in the airway, bronchoconstriction, and airway inflammation.
Methods
Bronchoalveolar lavage (BAL) cells from healthy horses and horses with asthma were collected and evaluated for cytology and MARCKS protein levels.
A specific inhibitor peptide known as Myristoylated N-terminal Sequence (MANS), designed to suppress MARCKS, was used on alveolar macrophages and peripheral blood neutrophils to observe its effect on cytokine secretion and respiratory burst.
Results
The researchers found out that horses with asthma had notably higher levels of MARCKS protein than healthy horses.
Meanwhile, the MANS peptide was deemed ineffective in influencing the release of TNFα or IL-8 from alveolar macrophages.
However, it was successful in mitigating the zymosan-stimulated respiratory burst in both alveolar macrophages and peripheral blood neutrophils.
Conclusions
Based on the findings, the researchers suggested that MARCKS could be potentially influential in the pathophysiology of equine asthma, and can be a focus for further research on severe neutrophilic asthma.
As a novel anti-inflammatory target, MARCKS holds potential in the development of new treatment modalities for asthma.
Cite This Article
APA
Conley HE, Davis KU, Adler KB, Lavoie JP, Sheats MK.
(2025).
MARCKS protein is a potential target in a naturally occurring equine model of neutrophilic asthma.
Respir Res, 26(1), 126.
https://doi.org/10.1186/s12931-025-03194-w
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Comparative Medicine Institute, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Davis, Kaori Uchiumi
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Comparative Medicine Institute, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Adler, Kenneth B
Comparative Medicine Institute, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Department of Molecular and Biomedical Science, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA.
Lavoie, Jean-Pierre
Département des Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC, J2S 2M2, Canada.
Sheats, M Katie
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA. mkpeed@ncsu.edu.
Comparative Medicine Institute, North Carolina State University, 1060 William Moore Dr, Raleigh, NC, 27607, USA. mkpeed@ncsu.edu.
MeSH Terms
Animals
Asthma / metabolism
Asthma / veterinary
Asthma / drug therapy
Asthma / immunology
Asthma / pathology
Horses
Neutrophils / drug effects
Neutrophils / metabolism
Neutrophils / immunology
Neutrophils / pathology
Myristoylated Alanine-Rich C Kinase Substrate
Disease Models, Animal
Membrane Proteins / antagonists & inhibitors
Membrane Proteins / metabolism
Bronchoalveolar Lavage Fluid / cytology
Bronchoalveolar Lavage Fluid / immunology
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors
Intracellular Signaling Peptides and Proteins / metabolism
Horse Diseases / metabolism
Horse Diseases / drug therapy
Horse Diseases / immunology
Macrophages, Alveolar / metabolism
Macrophages, Alveolar / drug effects
Cytokines / metabolism
Cells, Cultured
Grant Funding
T32 OD011130 / NIH HHS
D17EQ-029 / Morris Animal Foundation
Conflict of Interest Statement
Declarations. Ethics approval and consent to participate: Procedures and protocols for population A were approved by the North Carolina State University Institutional Animal Care and Use Committee (IACUC 16-0740O and 19–779). Samples for Population B were obtained from the Equine Respiratory Tissue Bank (ERTB) (Lavoie laboratory). Consent for publication: Not applicable. Competing interests: HC - The author declares that they have no competing interests. KD - The author declares that they have no competing interests. KA - Patents planned, issued or pending: Biomarck Corporation, Durham, NC. METHODS FOR REGULATING INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN. Inventors: Kenneth Adler, Suji Takashi, Indu Parikh, Linda Martin, and Yuehuva Li.Assignment: BioMarck and NC State University. Filed: 6/4/2009 US Patent: 8,563,689; Granted: October 22, 2013. KD - The author declares that they have no competing interests. MKS - The author declares that they have no competing interests.
References
This article includes 83 references
Hamilton D, Lehman H. Asthma phenotypes as a guide for current and biologic therapies.. Clin Rev Allergy Immunol 2020;59:160–74.
Maltby S, Tay HL, Yang M, Foster PS. Mouse models of severe asthma: Understanding the mechanisms of steroid resistance, tissue remodelling and disease exacerbation.. Respirology 2017;22:874–85.
Couëtil L, Cardwell J, Gerber V, Lavoie J, Léguillette R, EA R. Inflammatory airway disease of Horses–Revised consensus statement.. J Vet Intern Med 2016;30:503–15.
Ammar M, Bahloul N, Amri O, Omri R, Ghozzi H, Kammoun S, Zeghal K, Ben Mahmoud L. Oxidative stress in patients with asthma and its relation to uncontrolled asthma.. J Clin Lab Anal 2022;36:e24345.
Sundaram M, Cook HW, Byers DM. The MARCKS family of phospholipid binding proteins: regulation of phospholipase D and other cellular components.. Biochem Cell Biol 2004;82:191–200.
Ziemba BP, Falke JJ. A PKC-MARCKS-PI. 3K regulatory module links Ca 2 + and PIP 3 signals at the leading edge of polarized macrophages.. PLoS ONE 2018;13:e0196678.
Green TD, Crews AL, Park J, Fang S, Adler KB. Regulation of mucin secretion and inflammation in asthma; A role for MARCKS protein?. Biochim Biophys Acta 2011;1810:1110–3.
Eckert RE, Neuder LE, Park J, Adler KB, Jones SL. Myristoylated Alanine-Rich C-Kinase substrate (MARCKS) protein regulation of human neutrophil migration.. Am J Respir Cell Mol Biol 2010;42:586–94.
Takashi S, Park J, Fang S, Koyama S, Parikh I, Adler KB. A peptide against the N-Terminus of myristoylated Alanine-Rich C kinase substrate inhibits degranulation of human leukocytes in vitro.. Am J Respir Cell Mol Biol 2006;34:647–52.
Li J, D’Annibale-Tolhurst M, Adler K, Al E. A myristoylated alanine-rich C kinase substrate-related peptide suppresses cytokine mRNA and protein expression in LPS-activated canine neutrophils.. Am J Respir Cell Mol Biol 2013;48:314–21.
Green TD, Park J, Yin Q, Fang S, Crews AL, Jones SL, Adler KB. Directed migration of mouse macrophages in vitro involves myristoylated alanine-rich C-kinase substrate (MARCKS) protein.. J Leukoc Biol 2012;92:633–9.
Thelen M, Rosen A, Nairn AC, Aderem A. Tumor necrosis factor alpha modifies agonist-dependent responses in human neutrophils by inducing the synthesis and myristoylation of a specific protein kinase C substrate.. Proc. Nati. Acad. Sci. USA 1990;87:5603–5607.
Wang C-N, Lin Y-C, Chang B-C, Chen C-H, Wu R, Lee C-C. Targeting the phosphorylation site of myristoylated alanine-rich C kinase substrate alleviates symptoms in a murine model of steroid-resistant asthma.. Br J Pharmacol 2019;176:1122–34.
Davarinejad H. accessed on Dec 13, Quantifications of Western Blots with ImageJ Available online: https://www.yorku.ca/yisheng/Internal/Protocols/ImageJ.pdf (2024).
Ainsworth D, Wagner B, Franchini M, Grunig G, Erb H, Tan J. Time-dependent alterations in gene expression of interleukin-8 in the bronchial epithelium of horses with IFN-gamma and IL-8 production in Bronchoalveolar lavage cells.. Am J Vet Res 2006;67:669–77.
Lee SM, Suk K, Lee WH. Myristoylated alanine-rich C kinase substrate (MARCKS) regulates the expression of Proinflammatory cytokines in macrophages through activation of p38/JNK MAPK and NF-κB.. Cell Immunol 2015;296:115–21.
Chen C-H, Thai P, Yoneda K, Adler KB, Yang P-C, Wu R. A peptide that inhibits function of myristoylated Alanine-Rich C kinase substrate (MARCKS) reduces lung cancer metastasis.. Oncogene 2014;33:3696–706.
Li Y, Martin LD, Spizz G, Adler KB. MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro.. J Biol Chem 2001;276:40982–90.
Agrawal A, Rengarajan S, Adler KB, Ram A, Ghosh B, Fahim M, Dickey BF. Inhibition of mucin secretion with MARCKS-related peptide improves airway obstruction in a mouse model of asthma.. J Appl Physiol 2007;102:399–405.
Yin Q, Fang S, Park J, Crews AL, Parikh I, Adler KB. An inhaled inhibitor of myristoylated Alanine-Rich C kinase substrate reverses LPS-Induced acute lung injury in mice.. Am J Respir Cell Mol Biol 2016;55:617–22.
Adler K, Kraft M, Parikh I, Murphy E, Van As A. Results of a phase 2a clinical trial with a peptide inhibitor of MARCKS protein indicate improvement of indices of bronchitis and lung function in patients with COPD.. Eur Respir J 2011;38:4901.
Anderson WH, Ceppe A, Rice C, Meyer NJ, Rice TW, Gibbs K, Adler KB, Carson SS. A Phase II. Placebo-Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients with Acute Respiratory Distress Syndrome.. In Proceedings of the TP52. TP052 ARDS STUDIES 2021;p. 2668.
Vargas A, Roux-Dalvai F, Droit A, Lavoie JP. Neutrophil-derived exosomes: A new mechanism contributing to airway smooth muscle remodeling.. Am J Respir Cell Mol Biol 2016;55:450–61.
Bubb MR, Lenox RH, Edison AS. Phosphorylation-dependent conformational changes induce a switch in the Actin-binding function of MARCKS.. J Biol Chem 1999;274:36472–8.
Huber R, Diekmann M, Hoffmeister L, Kühl F, Welz B, Brand K. MARCKS is an essential regulator of reactive oxygen species production in the monocytic cell type.. Antioxidants 2022;11:1600.
Damera G, Jester WF, Jiang M, Zhao H, Fogle HW, Mittelman M, Haczku A, Murphy E, Parikh I, Panettieri RA. Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation.. Exp Lung Res 2010;36:75–84.
Lee C-C, Chen C-H, Kenyon NJ, Wang C-N, Tsai H-C, Chiu C-L, Chen Y, Forteza RM, Wu R. Inhibition of MARCKS phosphorylation attenuates of dendritic cell migration in a murine model of acute asthma.. Eur J Pharmacol 2024;980.
Rombouts K, Mello T, Liotta F, Galli A, Caligiuri A, Annunziato F, Pinzani M. MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells.. Am J Physiol Cell Physiol 2012.
Toledo A, Zolessi FR, Arruti C. A novel effect of MARCKS phosphorylation by activated PKC: the dephosphorylation of its Serine 25 in chick neuroblasts.. PLoS ONE 2013;8:e62863.
Machlus KR, K WS, Stumpo DJ, Soussou TS, Paul DS, Campbell RA, Kalwa H, Michel T, Bergmeier W, Weyrich AS. Synthesis and dephosphorylation of MARCKS in the late stages of megakaryocyte maturation drive proplatelet formation.. Blood 2016;127:1468–80.
Kim SS, Kim JH, Lee S-H, Chung SS, Bang O-S, Park D, Chung CH. Involvement of protein phosphatase-1-mediated MARCKS translocation in myogenic differentiation of embryonic muscle cells.. J Cell Sci 2022;115:2465–73.
Brudvig JJ, Weimer JM, Cancedda L, Barnes AP, Newbern J. X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease.. Front Cell Neurosci 2015;9.
Poole J, Gleason A, Bauer C, Al E. CD11c(+)/CD11b(+) cells are critical for organic dust-elicited murine lung inflammation.. Am J Respir Cell Mol Biol 2012;47:652–9.
Carballo E, Pitterle DM, Stumpo DJ, Sperling RT, Blackshear PJ. Phagocytic and Macropinocytic activity in MARCKS-deficient macrophages and fibroblasts.. Am J Physiol 1999;277:C163–73.
Baert K, Sonck E, Goddeeris B, Cox E. Complement receptor 3 plays a significant role in β-glucan induced ROS production by porcine neutrophils.. In Proceedings of the In New Perspectives on Immunity to Infection, Abstracts 2012.
van Bruggen R, Drewniak A, Jansen M, van Houdt M, Roos D, Chapel H, Verhoeven AJ, Kuijper TW. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles.. Mol Immunol 2009;47:575–81.
Serrander L, Larsson J, Lundqvist H, Lindmark M, Fällman M, Dahlgren C, Stendahl O. Particles binding β2-integrins mediate intracellular production of oxidative metabolites in human neutrophils independently of phagocytosis.. Biochim Biophys Acta - Mol Cell Res 1999;1452:133–44.
Nakamoto K, Watanabe M, Sada M, Inui T, Nakamura M, Honda K, Wada H, Mikami Y, Matsuzaki H, Horie M, Noguchi S. Serum reactive oxygen metabolite levels predict severe exacerbations of asthma.. PLoS ONE 2016;11(10):e0164948.
Agrawal A, Murphy III, Park EC, Adler J, Parikh KB. BIO-11006, a novel MARCKS-related peptide, improves airway obstruction in a mouse model of mucus hypersecretion.. J Epithel Biol Pharmacol 2011;4:1–6.